Celgene Corp (CELG) 150.13 $CELG
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
How Will Biotech Fare the Rest of the Year?
George Budwell, The Motley Fool - Motley Fool - Fri May 23, 5:30PM CDT
Biotech has had a fairly volatile year thus far. Shares of the closely watched iShares Nasdaq Biotech Index , for instance, have swung from double-digit gains to high single-digit losses at one point this year. With the index now roughly flat for...
Final Glance: Biotechnology companies
AP - Fri May 23, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Celgene Gains Slightly on Management Changes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 3:12PM CDT
Shares of Celgene (CELG) gained slightly following the announcement of a series of organizational changes.
Midday Glance: Biotechnology companies
AP - Fri May 23, 12:40PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri May 23, 9:39AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Look for Shares of Celgene to Potentially Pullback after Yesterday's 1.57% Rise
Comtex SmarTrend(R) - Thu May 22, 3:49PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $148.00 to a high of $151.78. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $149.60 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Celgene Set to Possibly Pullback After Yesterday's Rally of 1.57%
Comtex SmarTrend(R) - Thu May 22, 3:49PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $148.00 to a high of $151.78. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $149.60 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Today's Top Health Care Stocks to Watch: Celgene Corporation and Sarepta Therapeutics, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu May 22, 7:55AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Celgene Corp. and Sarepta Therapeutics . Celgene announces changes to its leadership team One of biotech's top names announced major changes to its...
Organizational Changes Strengthen and Expand Celgene Leadership Team
Business Wire - Thu May 22, 5:00AM CDT
Celgene Corporation (NASDAQ:CELG) today announced organizational changes that will go into effect on August 1, 2014.
1 Breakthrough, 3 Beneficiaries: AbbVie Inc., Bristol Myers Squibb Co., and Celgene Corporation
Keith Speights, The Motley Fool - Motley Fool - Wed May 21, 5:30PM CDT
A little good news can sometimes go a long way. On Monday, Bristol-Myers Squibb and AbbVie announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for multiple myeloma drug elotuzumab. This news bodes...
Celgene Inks Licensing Deal with AADi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 10:30AM CDT
Celgene (CELG) has out licensed ABI-009 to AADi.
Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth
PR Newswire - Wed May 21, 7:41AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Celgene Corporation (NASDAQ: CELG), Novartis AG (NYSE: NVS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2747-100free.
AADi signs licensing agreement with Celgene for nanotechnology-based drug candidate ABI-009
M2 - Wed May 21, 4:02AM CDT
Biopharmaceutical company AADi stated on Tuesday that it has entered into an agreement to license the nanotechnology drug candidate ABI-009 from Celgene (NasdaqGS:CELG).
Biotech Tweet of the Week: Share Buybacks
Brian Orelli, The Motley Fool - Motley Fool - Tue May 20, 5:30PM CDT
We've got a pair of related tweets on this week's episode of Biotech Banter . The first is from Jason Napodano, an analyst at Zacks, who asks, "Does anyone actually finish a share buyback in biotech, or do they just announced another one after they...
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
How Will Biotech Fare the Rest of the Year?
George Budwell, The Motley Fool - Motley Fool - Fri May 23, 5:30PM CDT
Biotech has had a fairly volatile year thus far. Shares of the closely watched iShares Nasdaq Biotech Index , for instance, have swung from double-digit gains to high single-digit losses at one point this year. With the index now roughly flat for...
Final Glance: Biotechnology companies
AP - Fri May 23, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Celgene Gains Slightly on Management Changes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 23, 3:12PM CDT
Shares of Celgene (CELG) gained slightly following the announcement of a series of organizational changes.
Midday Glance: Biotechnology companies
AP - Fri May 23, 12:40PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri May 23, 9:39AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Look for Shares of Celgene to Potentially Pullback after Yesterday's 1.57% Rise
Comtex SmarTrend(R) - Thu May 22, 3:49PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $148.00 to a high of $151.78. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $149.60 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Celgene Set to Possibly Pullback After Yesterday's Rally of 1.57%
Comtex SmarTrend(R) - Thu May 22, 3:49PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $148.00 to a high of $151.78. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $149.60 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Today's Top Health Care Stocks to Watch: Celgene Corporation and Sarepta Therapeutics, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu May 22, 7:55AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Celgene Corp. and Sarepta Therapeutics . Celgene announces changes to its leadership team One of biotech's top names announced major changes to its...
Organizational Changes Strengthen and Expand Celgene Leadership Team
Business Wire - Thu May 22, 5:00AM CDT
Celgene Corporation (NASDAQ:CELG) today announced organizational changes that will go into effect on August 1, 2014.
1 Breakthrough, 3 Beneficiaries: AbbVie Inc., Bristol Myers Squibb Co., and Celgene Corporation
Keith Speights, The Motley Fool - Motley Fool - Wed May 21, 5:30PM CDT
A little good news can sometimes go a long way. On Monday, Bristol-Myers Squibb and AbbVie announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for multiple myeloma drug elotuzumab. This news bodes...
Celgene Inks Licensing Deal with AADi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 10:30AM CDT
Celgene (CELG) has out licensed ABI-009 to AADi.
Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth
PR Newswire - Wed May 21, 7:41AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Celgene Corporation (NASDAQ: CELG), Novartis AG (NYSE: NVS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2747-100free.
AADi signs licensing agreement with Celgene for nanotechnology-based drug candidate ABI-009
M2 - Wed May 21, 4:02AM CDT
Biopharmaceutical company AADi stated on Tuesday that it has entered into an agreement to license the nanotechnology drug candidate ABI-009 from Celgene (NasdaqGS:CELG).
Biotech Tweet of the Week: Share Buybacks
Brian Orelli, The Motley Fool - Motley Fool - Tue May 20, 5:30PM CDT
We've got a pair of related tweets on this week's episode of Biotech Banter . The first is from Jason Napodano, an analyst at Zacks, who asks, "Does anyone actually finish a share buyback in biotech, or do they just announced another one after they...
